As­traZeneca's prized Imfinzi/treme­li­mum­ab com­bo fails again — this time in head and neck can­cer

As­traZeneca’s big bet on a com­bi­na­tion of its check­point in­hibitor Imfinzi and in-house CT­LA-4 drug has proved ex­ceed­ing­ly cost­ly. The British drug­mak­er con­ced­ed on Fri­day …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER